Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Meds Apotek AB is a Swedish online pharmacy that provides a comprehensive digital platform for the sale and delivery of pharmaceutical and healthcare products. Founded in 2016 and launched in 2018, the company operates exclusively online, focusing on convenient access to a broad assortment of over 40,000 items, including prescription and over-the-counter medicines, supplements, beauty products, wellness goods, and pet medicines. Meds Apotek AB is fully licensed by the Swedish Medical Products Agency, ensuring regulatory compliance and service quality. The company emphasizes fast and reliable delivery, often providing same-day dispatch to customers across Sweden, and offers continuous access to pharmacist advice and customer support via digital channels. Meds Apotek AB stands out in the Nordic healthcare sector through its direct-to-consumer e-commerce model, leveraging advanced logistics and digital tools, including telemedicine and AI interfaces, to enhance user experience and operational efficiency. Its market significance is reflected in its rapid growth—achieving average annual net sales increases of nearly 39% in recent years and maintaining profitability since late 2024. Meds Apotek AB plays a pivotal role in the ongoing digital transformation of pharmacy services in the Nordic region.
kr 1.80
kr 0.01 (-0.28%)
Live · 10:48 PM · Twelve Data
The business is unprofitable at the operating level (-0.25% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 21.4%, still solid. Free cash flow declined 339% despite revenue growth, conversion is weakening.
Free cash flow declined 339% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -kr 29M. The business is consuming cash, not generating it.
4.6x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 1.03B
▲ +21.4% YoY
Net Income (TTM)
kr 8M
▲ +174.3% YoY
Op. Margin
-0.27%
▲ +0.8pp YoY
ROIC
-1.81%
▲ +4.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 15M
▼ -339.1% YoY
Op. Cash Flow (TTM)
-kr 13M
▼ -325.8% YoY
Net Debt
-kr 38M
Net Cash Position
Cash & Equiv.
kr 45M
Continue Research
At a P/E of 4.6, Meds Apotek AB (MEDS.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Meds Apotek AB scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Meds Apotek AB scores 50 out of 100 on Intrinsiqq's quality score, passing 4 of 7 checks, which makes it a mixed business on these measures. Recent fundamentals include a -0.3% operating margin and a -1.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh MEDS.XSTO's valuation and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.